Antimicrobial peptide PJX13 and its application in the prevention and control of citrus canker
By inhibiting Xanthomonas citrus through the modified antimicrobial peptide PJX13, the problem of citrus canker disease control has been solved, achieving efficient and environmentally friendly disease control with strong bactericidal activity and low risk of drug resistance.
Patent Information
- Application Number
- CN202512001929.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-12-29
- Publication Date
- 2026-05-26
AI Technical Summary
Existing chemical control methods are inefficient and unsustainable against citrus canker. Long-term use of copper-based agents leads to environmental pollution, antibiotics cause rapid development of antibiotic resistance in pathogens, and there is a lack of effective antimicrobial peptides against Xanthomonas citrus.
An antimicrobial peptide PJX13 is provided, which is prepared into water extract, powder, tincture, oil, emulsion or aerosol through acetyl and amidation modified amino acid sequences. It is used to inhibit Xanthomonas citrus, Staphylococcus aureus, Escherichia coli and rice blast fungus, destroy the cell membrane integrity of pathogens, and inhibit and kill citrus canker.
The antimicrobial peptide PJX13 effectively inhibits the spread of lesions on detached citrus leaves and living plants. Its bactericidal activity is stronger than that of traditional chemical agents. It is environmentally friendly, does not easily induce drug resistance, and significantly reduces the occurrence and development of citrus canker.
Smart Images

Figure CN122080138A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biopharmaceutical manufacturing technology. More specifically, it relates to the antimicrobial peptide PJX13 and its application in the prevention and treatment of citrus canker. Background Technology
[0002] Citrus canker is caused by Xanthomonas citrus subsp. (Citrus canker) Xanthomonas citri Citrus canker is a bacterial disease caused by *Citrus subsp. Citri* (Xcc). It primarily affects the leaves, shoots, and fruit of citrus trees, leading to leaf drop, twig dieback, fruit drop, and scarred or deformed fruit. This not only impacts citrus yield but also quality and commercial value, causing significant economic losses and hindering the healthy development of the citrus industry. Currently, the control of citrus canker mainly relies on copper-based fungicides and a few antibiotics (such as streptomycin sulfate). However, long-term reliance on copper-based agents has led to soil copper accumulation and environmental pollution, while the continued use of antibiotics faces the serious challenge of rapid development and spread of antibiotic resistance in pathogens, continuously reducing the efficiency and sustainability of existing chemical control methods. Therefore, the development of novel, highly effective, low-toxicity, environmentally compatible control agents that are less likely to induce resistance has become an urgent need to ensure the healthy development of the citrus industry.
[0003] Antimicrobial peptides (AMPs) are a class of small molecule polypeptides with antimicrobial activity, possessing the advantage of not easily inducing drug resistance. However, most existing antimicrobial peptides suffer from drawbacks such as complex preparation, high production costs, and poor stability, failing to maintain good stability and sustained activity in complex field environments. Furthermore, although several antimicrobial peptides have been reported, there is still a lack of antimicrobial peptides that can effectively combat *Xanthomonas citrus* and effectively inhibit the occurrence and development of citrus canker at the in vivo level. Summary of the Invention
[0004] To address the shortcomings of the prior art, this invention provides an antimicrobial peptide PJX13, which is effective against Xanthomonas citrus and can be used to prevent and treat citrus canker.
[0005] The above-mentioned objective of this invention is achieved through the following technical solution: This invention provides an antimicrobial peptide, PJX13, for the prevention and treatment of citrus canker. PJX13 is effective against *Xanthomonas citrus* and can effectively inhibit the spread of lesions on both detached citrus leaves and living plants. Furthermore, PJX13 can also inhibit *Escherichia coli*, *Staphylococcus aureus*, and *Bacillus oryzae*, and can be used to prepare broad-spectrum antibacterial products. Therefore, this invention seeks protection for the antimicrobial peptide PJX13 and its applications.
[0006] This invention provides an antimicrobial peptide PJX13, which is obtained by modifying the amino acid sequence shown in SEQ ID NO.1 with acetyl and amino capping.
[0007] Specifically, the N-terminus of the antimicrobial peptide PJX13 is acetylated and the C-terminus is amidated.
[0008] The present invention also provides an antibacterial composition containing the antibacterial peptide PJX13.
[0009] Optionally, the composition may further contain excipients.
[0010] Optionally, the antibacterial composition may be in the form of an aqueous extract, powder, tincture, oil, emulsion, or aerosol.
[0011] This invention seeks protection for the use of the antimicrobial peptide PJX13 or the antimicrobial composition in the fight against pathogens.
[0012] The present invention also claims protection for the use of the antimicrobial peptide PJX13 or the antimicrobial composition in the preparation of products for use against pathogenic bacteria.
[0013] Specifically, the pathogens are Escherichia coli, Staphylococcus aureus, Xanthomonas citrus, and / or rice blast fungus.
[0014] Specifically, the present invention seeks protection for the use of the antimicrobial peptide PJX13 or the antimicrobial composition against Xanthomonas citrus.
[0015] Specifically, this invention seeks protection for the use of the antimicrobial peptide PJX13 or the antimicrobial composition in the preparation of products resistant to Xanthomonas citrus.
[0016] Specifically, the present invention seeks protection for the use of the antimicrobial peptide PJX13 or the antimicrobial composition in inhibiting Escherichia coli, Staphylococcus aureus and / or rice blast fungus.
[0017] Specifically, this invention seeks protection for the use of the antimicrobial peptide PJX13 or the antimicrobial composition in the preparation of products that inhibit Escherichia coli, Staphylococcus aureus, and / or rice blast fungus.
[0018] The present invention also claims protection for the use of the antimicrobial peptide PJX13 or the antimicrobial composition in the preparation of products for the prevention and treatment of bacterial diseases caused by Escherichia coli and / or Staphylococcus aureus infection.
[0019] The present invention also claims protection for the use of the antimicrobial peptide PJX13 or the antimicrobial composition in the prevention and control of plant diseases.
[0020] The present invention also claims protection for the use of the antimicrobial peptide PJX13 or the antimicrobial composition in the preparation of products for the prevention and control of plant diseases.
[0021] Specifically, the plant diseases mentioned are citrus canker and / or rice blast.
[0022] Specifically, the citrus canker is caused by Xanthomonas citrus (… Xanthomonas citri Caused by ).
[0023] More specifically, the *Xanthomonas citrus* is Xanthomonas citri subsp. Citri.
[0024] Specifically, the rice blast disease is caused by the rice blast fungus (… Magnaporthe oryzae Caused by ).
[0025] The present invention also provides a method for preparing the antimicrobial peptide PJX13, including direct synthesis, or generating the amino acid sequence using biological materials capable of generating the amino acid sequence encoded by SEQ ID NO.1, and then chemically modifying the amino acid sequence to obtain the peptide.
[0026] Specifically, the biological material capable of generating the amino acid sequence shown in SEQ ID NO.1 includes a gene sequence encoding the amino acid sequence shown in SEQ ID NO.1, an expression cassette containing the gene sequence, a recombinant vector, or a recombinant bacterium containing the recombinant vector.
[0027] Optionally, the gene sequence encoding the amino acid sequence shown in SEQ ID NO.1 is shown in SEQ ID NO.2.
[0028] The present invention has the following beneficial effects: This invention provides an antimicrobial peptide, PJX13, which inhibits and kills *Xanthomonas citrus* by disrupting the cell membrane integrity of pathogens, leading to intracellular leakage. It exhibits strong bactericidal activity, with a minimum inhibitory concentration (MIC) significantly lower than that of the traditional chemical agent streptomycin sulfate, demonstrating superior bactericidal efficiency and speed of action. Evaluation of the inhibitory activity of antimicrobial peptide PJX13 against citrus canker also shows that it effectively inhibits lesion expansion on both detached citrus leaves and living plants, and can be formulated into an antimicrobial product against *Xanthomonas citrus* for the prevention and control of citrus canker. Furthermore, the antimicrobial peptide PJX13 of this invention can also inhibit *Escherichia coli*, *Staphylococcus aureus*, and *Bacillus oryzae*, and can be used to prepare broad-spectrum antimicrobial products. This invention is beneficial for the prevention and control of citrus canker, and has advantages such as being environmentally friendly and unlikely to induce drug resistance. Attached Figure Description
[0029] Figure 1 The figure shows the purity and molecular weight detection results of antimicrobial peptide PJX13 and its predicted three-dimensional structure. Figure a is the high performance liquid chromatography (HPLC) chromatogram of antimicrobial peptide PJX13; b is the mass spectrum of antimicrobial peptide PJX13; and c is the predicted three-dimensional structure of antimicrobial peptide PJX13.
[0030] Figure 2The statistical results of the inhibition zone diameters of each treatment well were used to determine the antimicrobial activity of the antimicrobial peptide PJX13 against Xanthomonas citrus. p <0.001.
[0031] Figure 3 The figures show the colony growth under different treatments in the determination of the minimum bactericidal concentration of the antimicrobial peptide PJX13; in the figure, a represents the colony growth after treatment with different concentrations of streptomycin sulfate; and b represents the colony growth after treatment with different concentrations of antimicrobial peptide PJX13.
[0032] Figure 4 The results show the antibacterial activity of antimicrobial peptide PJX13 against Escherichia coli. Figure a represents the plates coated with Escherichia coli, where ddH2O was added to 1, antimicrobial peptide PJX13 to 2, kanamycin sulfate to 3, and streptomycin sulfate to 4. Figure b represents the statistical results of the inhibition zone diameters of each treatment well. Different letters indicate that the variance analysis was significant at the 0.05 level.
[0033] Figure 5 The results show the antibacterial activity of the antimicrobial peptide PJX13 against Staphylococcus aureus. Figure a shows the plates coated with Staphylococcus aureus, where ddH2O was added to 1, kanamycin sulfate to 2, antimicrobial peptide PJX13 to 3, and streptomycin sulfate to 4. Figure b shows the statistical results of the inhibition zone diameter of each treatment well. Different letters indicate that the variance analysis was significant at the 0.05 level.
[0034] Figure 6 The results show the antibacterial activity of antimicrobial peptide PJX13 against rice blast fungus; in the figure, a represents the effect of different concentrations of antimicrobial peptide PJX13 on the germination of rice blast fungus spores; b represents the effect of different concentrations of antimicrobial peptide PJX13 on the germination rate of rice blast fungus spores; different letters indicate that the variance analysis was significant at the 0.05 level.
[0035] Figure 7 The results of the efficacy evaluation of antimicrobial peptide PJX13 against citrus canker (inoculation by detached leaf injection method) are shown in the figure. a is the negative control group, b is the streptomycin sulfate treatment group, and c is the antimicrobial peptide PJX13 treatment group.
[0036] Figure 8 The results of the efficacy evaluation of antimicrobial peptide PJX13 against citrus canker (inoculation by needle puncture of detached leaves); in the figure, a is the negative control group; b is the streptomycin sulfate treatment group; and c is the antimicrobial peptide PJX13 treatment group.
[0037] Figure 9The results of the efficacy evaluation of antimicrobial peptide PJX13 against citrus canker (live inoculation by needle prick method) are shown in the figure. a is the healthy control group; b is the disease control group; c is the streptomycin sulfate treatment group; d is the antimicrobial peptide PJX13 treatment group; e is the control group treated with antimicrobial peptide alone.
[0038] Figure 10 The growth curves of Xanthomonas citrus under different treatment conditions are shown.
[0039] Figure 11 Time-sterilization curves of Xanthomonas citrus under different treatment conditions.
[0040] Figure 12 Sugar content of Xanthomonas citrus under different treatment conditions.
[0041] Figure 13 The figure shows the protein content of Xanthomonas citrus under different treatment conditions; the values in the figure are expressed as mean ± standard error; one-way ANOVA was used for different treatments within the group, and multiple comparisons and significance analysis were performed using Duncan's method. Different letters indicate that the differences in ANOVA were significant at the 0.05 level.
[0042] Figure 14 The images show scanning electron microscopy (SEM) observations of Xanthomonas citrus; image a is the negative control group; image b is the group treated with the antimicrobial peptide PJX13.
[0043] Figure 15 Images of Xanthomonas citrus under transmission electron microscopy (TEM); a in the image is the negative control group; b is the image of the group treated with the antimicrobial peptide PJX13. Detailed Implementation
[0044] The present invention will be further described below with reference to the accompanying drawings and specific embodiments, but the embodiments do not limit the present invention in any way. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in this technical field.
[0045] Unless otherwise specified, all reagents and materials used in the following examples are commercially available.
[0046] The *Xanthomonas citrus* used in the embodiments of this invention ( Xanthomonas citri ) is a subspecies of Xanthomonas citrus ( Xanthomonas citri subsp. Citri, Xcc) CZG strain was provided by the Citrus Research Center of South China Agricultural University; the rice blast fungus used ( Magnaporthe oryzae The pathogenic strain ZC13, a single spore isolated from the physiological race ZC group of rice blast fungus, was used. Escherichia coli The strain used was DH5α, and the Staphylococcus aureus used was... Staphylococcus aureusThe strains were all Xx3 and were provided by the National Joint Laboratory for Green Pesticides.
[0047] Example 1: Synthesis, structural prediction, and physicochemical property analysis of antimicrobial peptide PJX13 Through design and screening, this invention has yielded a novel antimicrobial peptide, named antimicrobial peptide PJX13, whose amino acid sequence is shown below (SEQ ID NO.1): KKFWKLRRWVKWIG.
[0048] The gene sequence encoding the amino acid sequence is shown below (SEQ ID NO.2): AAAGAAGTTCTGGAAGCTGAGACGCTGGGTGAAGTGGATCGGC.
[0049] This invention commissioned Shanghai Beyotime Biotechnology Co., Ltd. to synthesize the antimicrobial peptide PJX13, and simultaneously performed acetylation modification at its N-terminus and amidation modification at its C-terminus to enhance stability. The sequence of the modified antimicrobial peptide PJX13 is: Ac KKFWKLRRWVKWIG NH2.
[0050] For the antimicrobial peptide PJX13, the present invention used AlphaFold to predict its three-dimensional structure and further used NOVOPRO to analyze its physicochemical properties. The results are shown in Table 1.
[0051] Table 1 Physicochemical properties of antimicrobial peptide PJX13
[0052] Note: GRAVY represents the arithmetic mean of hydrophobicity coefficients, negative values indicate hydrophilicity, and the smaller the value, the more hydrophilic the peptide; Boman Index (>2) indicates the potential of the antimicrobial peptide to bind to proteins (or other ligands).
[0053] Table 1 shows that the isoelectric point of antimicrobial peptide PJX13 is 11.17, classifying it as a strongly basic peptide. According to GRAVY calculations, antimicrobial peptide PJX13 exhibits hydrophilicity, and its net charge is +6. This high net charge and good hydrophilicity together indicate good solubility in aqueous phases and common buffer systems (such as PBS), suggesting it is readily soluble in water. The predicted Boman Index value is >2, indicating that antimicrobial peptide PJX13 may be a multifunctional antimicrobial peptide.
[0054] Furthermore, the purity and molecular weight of the synthesized antimicrobial peptide PJX13 were detected by high performance liquid chromatography (HPLC) and mass spectrometry, respectively.
[0055] The HPLC chromatogram of the antimicrobial peptide PJX13 is shown below. Figure 1 As shown in Figure a, the antimicrobial peptide PJX13 exhibits a peak at 14.591 min and reaches its maximum peak at 14.839 min, with a peak height of 978786. This is a characteristic peak, and the spectrum shows a symmetrical distribution with high purity (96.023%). The mass spectrum of antimicrobial peptide PJX13 is shown below. Figure 1 As shown in b in the diagram. The molecular weight of the antimicrobial peptide PJX13 was determined to be 1926.32 Da, which is close to the predicted theoretical molecular weight. The predicted three-dimensional structure of the antimicrobial peptide PJX13 is shown in the diagram below. Figure 1 As shown in c in the figure, the antimicrobial peptide PJX13 exhibits a simple structure dominated by a single α-helix.
[0056] Example 2: Antimicrobial effect of antimicrobial peptide PJX13 against Xanthomonas citrus 1. Determination of the antimicrobial activity of antimicrobial peptide PJX13 against Xanthomonas citrus Using Xanthomonas citrus CZG strain as the test strain, the in vitro antibacterial activity of the antimicrobial peptide PJX13 was preliminarily evaluated by measuring the size and morphology of the inhibition zone formed by the diffusion of the drug in agar using the agar diffusion method.
[0057] (1) Experimental methods After activating Xanthomonas citrus CZG strain on NA plates, single colonies were picked and inoculated into NB liquid medium and cultured at 30°C with shaking until the logarithmic growth phase (OD200). 600 Approximately 0.6) was prepared for use. A 500 μg / mL solution of the antimicrobial peptide PJX13 was prepared using sterile ddH2O. A 500 μg / mL solution of streptomycin sulfate was used as a positive control, and sterile ddH2O was used as a negative control. In a clean bench, 50 μL of CZG strain culture was added to a sterile petri dish, followed by approximately 20 mL of NA medium cooled to 45–50°C. The dish was gently shaken. After the agar had completely solidified, sterile perforators (approximately 6 mm in diameter) were used to make evenly spaced holes in the plate. 20 μL of the antimicrobial peptide PJX13 solution, a positive control, or a negative control was precisely added to each hole. The plate was then placed in a 28°C incubator and incubated for 24–48 h. After incubation, the diameter and morphological characteristics of the inhibition zone around each treatment well were observed and measured. The diameter of the inhibition zone (including the hole diameter) was measured using calipers, and the average value of three replicates was taken.
[0058] (2) Experimental results The statistical results of the inhibition zone diameters of the antimicrobial peptide PJX13, positive control, and negative control wells are as follows: Figure 2 As shown. By Figure 2It can be seen that the antimicrobial peptide PJX13 has a significant inhibitory effect on Xanthomonas citrus, and the diameter of the inhibition zone produced is about 12.15 mm. The positive control streptomycin sulfate also has a significant inhibitory effect, and the diameter of the inhibition zone produced is about 15.51 mm. However, no inhibition zone was observed around the well of the negative control ddH2O.
[0059] The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of the antimicrobial peptide PJX13 were then determined by microdilution.
[0060] 2. MIC determination of antimicrobial peptide PJX13 Using *Xanthomonas citrinum* CZG strain as the test strain, the MIC of the antimicrobial peptide PJX13 against *Xanthomonas citrinum* was determined using the micro-broth dilution method with an ELISA reader. The micro-broth dilution method accurately determines the minimum drug concentration required to completely inhibit visible bacterial growth by detecting changes in optical density under a series of drug concentrations.
[0061] (1) Experimental methods The assay system consisted of four groups: experimental group: bacterial suspensions containing different concentrations of the antimicrobial peptide PJX13; positive control group: bacterial suspensions containing different concentrations of streptomycin sulfate; negative control group: pure bacterial suspensions without the drug; and blank control group: pure culture medium without bacteria. Each group was replicated in triplicate to ensure the reproducibility of the results.
[0062] Take the CZG strain culture in the logarithmic growth phase and adjust the concentration to 5 × 10⁻⁶ with sterile NA liquid medium. 5 CFU / mL bacterial suspension; antimicrobial peptide stock solution, streptomycin sulfate stock solution, and liquid culture medium were serially diluted 2-fold to prepare a series of concentrations of 1 mg / mL, 500, 250, 125, 62.5, 31.25, 16, and 8 μg / mL. These were then mixed with an equal volume of bacterial suspension in sterile 96-well plates to obtain mixtures with final concentrations of 500, 250, 125, 62.5, 31.25, 16, 8, and 4 μg / mL. Negative controls and blank controls were added in equal volumes of their respective solutions. The 96-well plates were incubated at 30°C in a shaker for 4 h. Immediately after incubation, the absorbance (OD) of each well was measured at 600 nm using a microplate reader. 600 The blank control wells were zeroed, and the inhibitory effect of the antimicrobial peptides on bacterial growth was evaluated by comparing the absorbance values of each group with the negative control group; samples were taken for visual inspection to ensure the absorbance of the wells was clear and the OD value was within the range of 100%. 600 The lowest drug concentration at which the value shows no significant difference from the blank control (indicating complete inhibition of bacterial growth) is defined as the MIC value of the drug. All experiments were independently repeated three times.
[0063] (2) Experimental results The MIC determination results of the antimicrobial peptide PJX13 are shown in Table 2.
[0064] Table 2. MICs of antimicrobial peptide PJX13 and streptomycin sulfate against Xanthomonas citrus
[0065] As shown in Table 2, the antimicrobial peptide PJX13 exhibited significant inhibitory activity against Xanthomonas citrus. The MIC value of the positive control streptomycin sulfate was 250 μg / mL, while the MIC value of the antimicrobial peptide PJX13 was 31.25 μg / mL, which was significantly lower than that of streptomycin sulfate.
[0066] 3. MBC determination of antimicrobial peptide PJX13 To clarify the bactericidal ability of the antimicrobial peptide PJX13, its MBC (the minimum drug concentration that can kill more than 99.9% of the test bacteria) was further determined based on its MIC.
[0067] (1) Experimental methods Take the CZG strain culture in the logarithmic growth phase and adjust the concentration to 10 with sterile physiological saline. 6 CFU / mL; The bacterial culture was mixed with equal volumes of antimicrobial peptide solution and streptomycin sulfate solution to ensure the final drug concentration covered its MIC value and higher concentrations (e.g., 1×MIC, 2×MIC, 4×MIC, etc.); the mixture was incubated at 30℃ for 4 h, and then 100 μL of the mixture was spread onto NA solid plates, with three replicates for each concentration; the plates were incubated at 28℃ for 48 h, and colony growth was observed; the lowest drug concentration at which no colonies grew on the plate was recorded as MBC. The MBC / MIC ratio was also calculated to preliminarily determine the bactericidal properties of the drug (generally, MBC / MIC ≤ 4 indicates that the drug has bactericidal activity).
[0068] (2) Experimental results In the MBC assay of antimicrobial peptide PJX13, the colony growth of different treatments was as follows: Figure 3 As shown; Figure 3 In the figures, 'a' represents the colony growth after treatment with different concentrations of streptomycin sulfate; 'b' represents the colony growth after treatment with different concentrations of the antimicrobial peptide PJX13. Figure 3 The MBC of the antimicrobial peptide PJX13 was 125 μg / mL, and its MBC / MIC ratio was ≤4, indicating that it has bactericidal activity. In contrast, the MBC of the positive control streptomycin sulfate was as high as 8 mg / mL, far exceeding that of the antimicrobial peptide treatment group. Furthermore, streptomycin sulfate had a larger MBC / MIC ratio, suggesting that its bactericidal efficiency was lower at the tested concentration.
[0069] The above results indicate that the antimicrobial peptide PJX13 not only has an inhibitory effect on Xanthomonas citrus, but also achieves effective bactericidal activity at low concentrations, with bactericidal activity significantly superior to that of the traditional antibiotic streptomycin sulfate.
[0070] Example 3: Antimicrobial effect of antimicrobial peptide PJX13 against other pathogens In addition to testing the inhibitory effect of the antimicrobial peptide PJX13 on Xanthomonas citrus, this invention also tested whether the antimicrobial peptide PJX13 has an inhibitory effect on other pathogens.
[0071] 1. Determination of the antimicrobial activity of antimicrobial peptide PJX13 against Escherichia coli / Staphylococcus aureus The antimicrobial activity of the antimicrobial peptide PJX13 against *Escherichia coli* / *Staphylococcus aureus* was tested using the agar diffusion method described in Example 2. LB medium was used, and the reagents included kanamycin sulfate, streptomycin sulfate, and the antimicrobial peptide PJX13 at a concentration of 10 mg / mL, with 50 μL added to each well.
[0072] The results of the antimicrobial activity assay of antimicrobial peptide PJX13 against Escherichia coli are as follows: Figure 4 As shown. By Figure 4 It can be seen that the antimicrobial peptide PJX13, kanamycin sulfate, and streptomycin sulfate can all inhibit Escherichia coli and produce inhibition zones on E. coli plates, while no clear zones are produced in the sterile water treatment group. Figure 4 (a) The inhibition zone diameter produced by the antimicrobial peptide PJX13 was 15.40 mm, significantly higher than that of the streptomycin sulfate and water treatment groups, but lower than that of the kanamycin sulfate treatment group. Figure 4 (b) in the middle.
[0073] The results of the antimicrobial activity assay of antimicrobial peptide PJX13 against Staphylococcus aureus are as follows: Figure 5 As shown. By Figure 5 It can be seen that the antimicrobial peptide PJX13, kanamycin sulfate, and streptomycin sulfate can all inhibit Staphylococcus aureus, producing inhibition zones on Staphylococcus aureus plates, while no clear zones are produced in the sterile water treatment group. Figure 5 (a) The inhibition zone diameter produced by the antimicrobial peptide PJX13 was 18.95 mm, significantly higher than that of streptomycin sulfate, kanamycin sulfate, and the water treatment group (a). Figure 5 (b) in the middle.
[0074] 2. Determination of the antimicrobial activity of antimicrobial peptide PJX13 against rice blast fungus Collect rice blast fungus spores and prepare a solution with a concentration of 1×10⁻⁶. 5CFU / mL spore suspensions were prepared, and different amounts of antimicrobial peptide solution were added to achieve final concentrations of 0.1 mmol / L and 0.01 mmol / L for the antimicrobial peptide PJX13. An equal volume of sterile ddH2O was added as a negative control. When the spore germination rate in the negative control group exceeded 90%, the number of germinating spores in each group was counted under a microscope, and appressorium formation was observed. The experiment was repeated three times, with at least 200 spores counted each time.
[0075] The results of the antimicrobial activity assay of antimicrobial peptide PJX13 against rice blast fungus are as follows: Figure 6 As shown. By Figure 6 It was found that the spores of *Strombus oryzae* germination were in good condition and the spore germination rate was high in the negative control group. However, the spore germination of the groups treated with antimicrobial peptide PJX13 at concentrations of 0.1 mmol / L and 0.01 mmol / L was inhibited, with spore germination rates of 7.79% and 53.89%, respectively, which were significantly lower than the 94.61% of the control group. Inhibition of *Strombus oryzae* spore germination will in turn affect its appressorium formation.
[0076] Example 4: Inhibitory effect of antimicrobial peptide PJX13 on citrus canker. 1. Evaluation of the inhibitory activity of antimicrobial peptide PJX13 on citrus canker in detached leaves (1) Preparation and inoculation of detached leaves Select uniformly sized, vigorous, and undamaged Wogan mandarin orange leaves. Wipe the surface with clean water and 75% alcohol in sequence, then rinse twice with sterile water, and finally wipe dry with sterile cotton.
[0077] Two inoculation methods were used to simulate different routes of infection: Injection inoculation: Gently prick the underside of the leaf with the tip of a sterile 1 mL syringe needle (without puncturing), and drip 10 μL of Xanthomonas citrus CZG strain suspension (OD200) into the wound. 600 =0.6), and then the bacterial solution was aspirated back and injected into the leaf tissue using a needleless syringe. The inoculation range was determined by the water stains that formed.
[0078] Needle-prick inoculation: After creating a micro-wound, 10 μL of bacterial suspension is dripped onto the wound and allowed to be absorbed naturally. This method is closer to the process of infection through natural wounds caused by rainwater in the field.
[0079] (2) Humidification culture and drug treatment After inoculation, the leaves were placed in disposable culture boxes lined with moist sponges, the petioles were wrapped with moist absorbent cotton, and the surface was covered with plastic wrap to keep them moist. The leaves were then cultured in the dark at 28°C and 80% humidity. Two treatments were administered on day 5 (when symptoms first appeared) and day 12 after inoculation: sterile filter paper was applied to the lesions, and 40 μL of 500 μg / mL antimicrobial peptide (PJX13), 500 μg / mL streptomycin sulfate (positive control), or sterile water (negative control) were added, respectively. Each treatment was replicated in triplicate.
[0080] (3) Observation and record of disease development Regularly observe and record the morphology of lesions, the production of bacterial ooze, and the overall health of the leaves. Conduct a systematic assessment and take photos on the 12th and 20th days after inoculation.
[0081] (4) Results Evaluation results of the efficacy of antimicrobial peptide PJX13 against citrus canker (inoculation method using detached leaf injection) are as follows: Figure 7 As shown, Figure 7 In the diagram, 'a' represents the negative control group, 'b' represents the streptomycin sulfate treatment group, and 'c' represents the antimicrobial peptide PJX13 treatment group. Figure 7 Five days after inoculation, leaves in all groups showed yellowish-green, oily, macerated spots. Twelve days after inoculation, the negative control group showed typical "crater"-shaped, grayish-white raised lesions accompanied by a large amount of bacterial ooze. The streptomycin sulfate treatment group showed similar lesions, but with a slightly lower degree of elevation. The PJX13 treatment group showed slightly raised lesions with very little bacterial ooze, and the center remained oily. Twenty days after inoculation, the lesions in the control group expanded to about 50% of the leaf area, showing a three-stage symptom pattern of a brown corky core, a chrome-yellow transition zone, and a yellowish-green halo around the periphery, and the leaves tended to wither. The expansion of lesions in the streptomycin sulfate group was slightly delayed. In the PJX13 treatment group, the bacterial ooze disappeared at the lesions, the tissue was locally necrotic, and only a slight chrome-yellow transition appeared around the lesions. The leaves remained green overall and did not wilt.
[0082] Evaluation results of the efficacy of antimicrobial peptide PJX13 against citrus canker (inoculation by needle prick on detached leaves) are as follows: Figure 8 As shown. By Figure 8 It was found that 5 days after inoculation, needle-like oily spots appeared on the leaves; 12 days after inoculation, the negative control group showed obvious bacterial ooze; the streptomycin sulfate treatment group showed yellow-green oily spots with a small amount of bacterial ooze at the edges; no bacterial ooze was observed in the PJX13 treatment group, and the wounds were brown; 20 days after inoculation, the brown color of the wounds in the PJX13 treatment group deepened, and a chlorotic halo appeared at the edges, indicating that it could effectively inhibit the formation of bacterial ooze.
[0083] The above results indicate that the antimicrobial peptide PJX13 significantly inhibited the infection and disease development of Xanthomonas citrus in both inoculation models, manifested as reduced bacterial ooze, decreased lesion elevation, and a significant effect on leaf chlorosis. At the same concentration, its control effect was superior to that of streptomycin sulfate.
[0084] 2. Evaluation of the in vivo control effect of antimicrobial peptide PJX13 on Wogan tangerine canker. To evaluate the application potential of the antimicrobial peptide PJX13 in agricultural production, this invention further validated its control effect in a live Wogan mandarin orange plant system. The live environment is complex, involving multiple factors such as plant immunity, pesticide delivery stability, and host-pathogen-antimicrobial peptide interactions. Therefore, this invention used a needle-pricking inoculation method to simulate the natural infection process, uniformly inoculating and treating Wogan mandarin orange leaves of uniform growth, and systematically evaluating the control effect of the antimicrobial peptide PJX13 under real pathogenic conditions.
[0085] Evaluation results of the efficacy of antimicrobial peptide PJX13 against citrus canker (live inoculation via needle prick method) are as follows: Figure 9 As shown. By Figure 9 It was found that the needle-puncture wounds on the leaves of the healthy control group were basically healed and returned to a healthy state 20 days after inoculation. In the disease control group (inoculated only with *Xanthomonas citrinum*), a large amount of yellowish-green bacterial ooze appeared on both sides of the leaves, with grayish-white to light brown, volcano-like cracks in the center of the lesions, surrounded by corky raised areas and a yellow halo. The streptomycin sulfate treatment group (treated with streptomycin sulfate two days after inoculation with *Xanthomonas citrinum*) showed less symptom than the disease control group, but typical lesion characteristics were still visible. The antimicrobial peptide PJX13 treatment group (treated with antimicrobial peptide PJX13 two days after inoculation with *Xanthomonas citrinum*) showed only a small amount of rust-colored bacterial ooze on both sides of the leaves, with no obvious raised lesions on the leaf surface, only accompanied by a slight pale yellow halo. The antimicrobial peptide-only treatment control group (healthy leaves only coated with antimicrobial peptide, without inoculation with the pathogen) showed good wound healing, although not fully recovered to the level of the healthy group, but did not cause significant toxic side effects. The above results indicate that the antimicrobial peptide PJX13 can still effectively inhibit the occurrence and development of citrus canker at the in vivo level, and its antimicrobial mechanism has a certain continuity and transformation potential in the real pathogenic environment.
[0086] Example 5: Antimicrobial mechanism of antimicrobial peptide PJX13 This invention uses Xanthomonas citrus CZG strain as the test strain and analyzes the antimicrobial mechanism of antimicrobial peptide PJX13 by detecting the effects of antimicrobial peptide PJX13 on the growth, sugar content, protein content and cell morphology of the strain.
[0087] 1. Effects of antimicrobial peptide PJX13 on the growth of Xanthomonas citrus Xanthomonas citrinum was cultured to the logarithmic growth phase, and the cells were resuspended in fresh NA liquid medium. The OD600 was adjusted to 0.6 using a microplate reader. The experimental setup was as follows: The drug group was treated with a 1:1 volume ratio of antimicrobial peptide PJX13 solution to the bacterial culture to achieve the MIC concentration; the positive control group was treated with the same ratio of streptomycin sulfate to the bacterial culture to achieve the MIC concentration; the negative control group was treated with an equal volume of NA liquid medium to the bacterial culture; a blank control was prepared using pure NA medium. OD600 was measured immediately after sample addition at 600 nm using a microplate reader, and this was used as the initial value at 0 h. Measurements were then taken every 2 h for 24 h. Growth curves were plotted using Prism software. All experiments were independently repeated three times.
[0088] Growth curves of Xanthomonas citrus under different treatment conditions are as follows: Figure 10 As shown. By Figure 10 It was found that, compared with the streptomycin sulfate treatment group and the negative control group, the growth curve of *Xanthomonas citrinum* in the antimicrobial peptide PJX13 treatment group showed a more gradual increase, indicating that antimicrobial peptide PJX13 can effectively reduce the growth rate of *Xanthomonas citrinum* and decrease its final biomass. Calculation of the growth parameters of *Xanthomonas citrinum* using the growth curve fitting formula shown in Table 3 revealed that the lag phase in the control group was 3.15 h; after streptomycin sulfate treatment, the lag phase was prolonged to 5.19 h; while after antimicrobial peptide PJX13 treatment, the lag phase of *Xanthomonas citrinum* was significantly prolonged to 7.79 h, and the final biomass was also significantly reduced. The prolonged lag phase usually reflects the obstruction of the bacterial metabolic restart process, suggesting that antimicrobial peptide PJX13 may achieve highly efficient inhibition of *Xanthomonas citrinum* by interfering with the metabolic activity of the pathogen and delaying its adaptation and recovery process.
[0089] Table 3. Growth Curve Fitting Formulas and Growth Parameters
[0090] Note: f(x) = K / 1 + exp-r(x - x0); K: the limit of bacterial growth, representing the maximum number of bacteria that the environment can support; lag period: the point where the derivative f(x) reaches its maximum value, which marks the beginning of rapid growth of the curve, and the time period before the inflection point is defined as the lag period. Values are expressed as mean ± standard error; one-way ANOVA was used for different treatments within the group, and multiple comparisons and significance analysis were performed using Duncan's method (different letters indicate that the differences in ANOVA are significant at the 0.05 level).
[0091] 2. Time-bactericidal curve of antimicrobial peptide PJX13 against Xanthomonas citrus Xanthomonas citrus was cultured to the logarithmic growth phase, and the cells were resuspended in fresh NA liquid medium. The OD600 was adjusted to 0.6 using a microplate reader. The experimental setup was as follows: The drug group was treated with a 1:1 ratio of antimicrobial peptide PJX13 to the bacterial culture, achieving a final concentration equal to its MBC value; the positive control group was treated with the same ratio of streptomycin sulfate to the bacterial culture, achieving a final concentration equal to the MBC value; the negative control group was treated with an equal volume of NA liquid medium and the bacterial culture; a blank control was prepared using pure NA medium. Immediately after sample addition, the OD600 was measured at 600 nm using a microplate reader, which was used as the initial value at 0 h. Measurements were then taken every 2 h for 24 h. Time-kill curves were plotted using Prism software, and the experiment was independently repeated three times.
[0092] Time-sterilization curves of Xanthomonas citrus under different treatment conditions are as follows: Figure 11 As shown. By Figure 11 It was found that the antimicrobial peptide PJX13 exhibited a rapid bactericidal effect against Xanthomonas citrus. After 2 hours of treatment, the OD600 value of the PJX13 group was significantly lower than that of the normal bacterial suspension group and the streptomycin sulfate group, indicating that the antimicrobial peptide initiated the bactericidal process within 2 hours, leading to a decrease in bacterial count, consistent with the characteristics of a rapid bactericidal agent. With prolonged treatment time, from 10 to 20 hours, the OD600 value of the PJX13 group was significantly lower than that of the streptomycin sulfate group, which is speculated to be related to the bacterial cell rupture caused by PJX13, completely eliminating detectable bacterial count. In contrast, although the OD600 value of the streptomycin sulfate treatment group was significantly lower than that of the normal bacterial suspension group, it showed a slow upward trend, indicating that at this concentration, streptomycin sulfate could inhibit the proliferation of pathogens but did not have a rapid bactericidal ability.
[0093] 3. Effect of antimicrobial peptide PJX13 on sugar content of Xanthomonas citrus (1) Construction of glucose standard curve (anthrone colorimetric method) The reagents required to plot the glucose content standard curve are shown in Table 4.
[0094] Table 4. Reagents required for plotting the glucose content standard curve
[0095] Accurately weigh 0.1 g of anthrone, dissolve it in 80% sulfuric acid, and bring the volume to 50 mL to prepare the anthrone reagent. Prepare and use immediately. Add the samples sequentially according to the system in Table 4, mix well, heat in a 100℃ water bath for 7 min, remove and cool to room temperature, let stand for 10 min, use tube 1 as a blank control, and measure the absorbance at 620 nm using an ELISA reader. Plot a standard curve with glucose concentration on the x-axis and absorbance on the y-axis.
[0096] (2) Reagent preparation Anthrone reagent: Weigh 0.01 g of anthrone, dissolve it in an appropriate amount of 80% sulfuric acid, make up to 5 mL, and store in a brown bottle. Prepare fresh each time you use it.
[0097] 40% Trichloroacetic Acid: Weigh 40 g of trichloroacetic acid, slowly add it to sterile water while stirring continuously, and bring the volume to 100 mL.
[0098] (3) Bacterial solution treatment and sugar content determination Xanthomonas citrinum was cultured to the logarithmic growth phase, and the cells were resuspended in fresh NA liquid medium. The OD600 was adjusted to 0.6 using a microplate reader. The following experimental groups were set up: drug group (antimicrobial peptide was mixed with bacterial culture at a 1:1 volume ratio to achieve the MIC concentration), positive control group (streptomycin sulfate was mixed with bacterial culture at a 1:1 volume ratio to achieve the MIC concentration), and negative control group (an equal volume of NA medium was mixed with bacterial culture). Every 4 h, 1 mL of sample was taken, and an equal volume of 40% trichloroacetic acid was added. After thorough mixing, the mixture was centrifuged at 4000 r / min for 5 min, and the supernatant was used for anthrone colorimetric determination. 4 mL of anthrone reagent was added to the supernatant, mixed slowly, heated in a 100℃ water bath for 7 min, cooled to room temperature under running water, and allowed to stand for 10 min. The absorbance was measured at 620 nm. The sugar content of the samples was calculated based on the standard curve, and the sugar content of the bacterial culture in each treatment group was plotted over time.
[0099] (4) Results Sugar content of Xanthomonas citrus under different treatment conditions, such as Figure 12 As shown. By Figure 12 It was found that the sugar content of *Xanthomonas citrus* in the normal bacterial culture control, streptomycin sulfate treatment, and PJX13 treatment groups all showed a decreasing trend with prolonged culture time, indicating basal carbon source consumption. However, the rate and extent of sugar consumption differed significantly among the different treatment groups. Compared with the normal bacterial culture control group and the streptomycin sulfate treatment group, the residual sugar concentration in the PJX13 treatment group remained higher throughout the culture process, and its sugar concentration decrease curve was more gradual.
[0100] The above results demonstrate that the antimicrobial peptide PJX13 can effectively inhibit the uptake and utilization of sugars in the culture medium by pathogens, thus verifying its antibacterial activity at the metabolic level.
[0101] 4. Effects of antimicrobial peptide PJX13 on Xanthomonas citrus proteins (1) Drawing the standard curve The reagents required to plot the protein content standard curve are shown in Table 5.
[0102] Table 5. Reagents required for plotting the protein content standard curve
[0103] Referring to the system shown in Table 5, different volumes of 1 mg / mL standard protein solution and distilled water were added sequentially to each tube to make a final volume of 1 mL. Then, 5 mL of Coomassie Brilliant Blue G-250 reagent was added to each tube, and after thorough mixing for 2 min, the absorbance was immediately measured at 595 nm using a microplate reader. A standard curve was plotted with protein concentration (mg / mL) on the x-axis and absorbance values on the y-axis.
[0104] (2) Bacterial culture treatment and protein content determination Xanthomonas citrinum was cultured to the logarithmic growth phase, and the cells were resuspended in fresh NA liquid medium. The OD600 was adjusted to 0.6 using a microplate reader. The following experimental groups were set up: a drug group (antimicrobial peptide was mixed with bacterial culture at a 1:1 volume ratio to achieve a final concentration of its MBC value), a positive control group (streptomycin sulfate was mixed with bacterial culture at a 1:1 volume ratio to achieve a final concentration of its MBC value), and a negative control group (an equal volume of NA medium was mixed with bacterial culture). 200 μL samples were taken at 2 h, 4 h, and 6 h after treatment, centrifuged at 4000 r / min for 5 min, and the supernatant was diluted 5-fold with sterile water. Then, 5 mL of Coomassie Brilliant Blue G-250 reagent was added, and the mixture was thoroughly mixed for 2 min. The absorbance was measured at 595 nm. The protein content in the supernatant was calculated based on the standard curve, and its change over time was plotted.
[0105] (3) Results Protein content of Xanthomonas citrus under different treatment conditions, such as Figure 13 As shown. By Figure 13 It was found that the protein concentration in the supernatant of the bacterial culture varied significantly among the different treatment groups within 2–6 h. The protein concentration in the normal bacterial culture group continuously decreased, indicating that the bacteria continuously consumed protein from the culture medium during growth. The streptomycin sulfate treatment group also showed a decreasing trend, but its rate of decrease was lower than that of the normal group, and the protein concentration at 4 h and 6 h was significantly higher than that of the normal control group at the same time points, indicating that streptomycin sulfate reduced the utilization of protein by inhibiting bacterial growth. The protein concentration in the antimicrobial peptide PJX13 treatment group showed an increasing trend, and the concentration at each time point was significantly higher than that of the normal group and the streptomycin sulfate group. This may be related to the damage to the bacterial cell membrane / wall caused by PJX13, leading to the leakage of intracellular protein, thus further revealing its antimicrobial mechanism from the perspective of protein metabolism.
[0106] 5. Effects of antimicrobial peptide PJX13 on the morphology of Xanthomonas citrus (1) Observation of bacterial cell morphology by scanning electron microscopy (SEM) Pick a single colony from the plate and inoculate it to the logarithmic growth phase (OD). 600=0.6); Take 1.5 mL of bacterial suspension, centrifuge at 3000 r / min for 8 min, discard the supernatant, and resuspend the bacterial cells in 1 mL of NA liquid medium. Set up a drug group and a negative control group; Drug group: bacterial suspension and antimicrobial peptide PJX13 solution are mixed at a 1:1 volume ratio to make the final concentration of antimicrobial peptide its MBC value; Negative control group: bacterial suspension and NA liquid medium are mixed at a 1:1 volume ratio; Place the mixture in a 30℃ constant temperature shaker and incubate at 200 r / min for 8 h; After incubation, centrifuge at 3000 r / min for 8 min, discard the supernatant, and wash 1-3 times with PBS (pH 7.4) to remove residual drug solution. Place a scanning electron microscope coverslip in a 12-well plate, concentrate the washed bacterial suspension and drop it onto the coverslip, let stand for 3 min; gently rinse with PBS to remove excess bacterial suspension, add 2.5% glutaraldehyde fixative, seal the 12-well plate with sealing film, and store at 4℃ overnight. The fixative was discarded, and the sample was rinsed three times with PBS for 10 min each time. Subsequently, a gradient dehydration process was performed using 30%, 50%, 70%, 80%, and 90% ethanol solutions, with each concentration treated for 10 min. Finally, the sample was treated twice with 100% ethanol for 10 min each time. After drying with a critical point dryer, the sample was sputter-coated with gold using a vacuum coating system. Finally, the sample was observed and imaged under a low-power field emission scanning electron microscope (15,000× or 35,000×).
[0107] Scanning electron microscopy (SEM) images of Xanthomonas citrus as shown below Figure 14 As shown, Figure 14 Image a in the diagram represents the negative control group, and image b represents the group treated with the antimicrobial peptide PJX13. Figure 14 It can be seen that in low-magnification images (15,000× or 35,000×), the bacterial cells in the normal control group are densely distributed and have high coverage. Figure 14 (a); however, after treatment with the antimicrobial peptide PJX13, the number of bacteria decreased significantly, and cell rupture, leakage of contents, and cavity formation occurred. Figure 14 (b) This result further supports the inference that antimicrobial peptides have antibacterial effects and related mechanisms.
[0108] (2) Transmission electron microscopy (TEM) observation of ultrastructure Pick a single colony from the plate and inoculate it to the logarithmic growth phase (OD). 600=0.6); Take 1.5 mL of bacterial culture, centrifuge at 3000 r / min for 8 min, discard the supernatant, and resuspend the bacterial cells in 1 mL of NA liquid medium. Set up a drug group and a negative control group, and follow the same procedure as in the SEM bacterial cell morphology observation section; place the mixed system in a 30℃ constant temperature shaker and incubate at 200 r / min for 6 h. After incubation, centrifuge at 3000 r / min for 4 min to collect the bacterial cells, discard the supernatant, and wash twice with PBS (pH 7.4) to completely remove residual drugs, followed by double fixation; pre-fixation: add an equal volume of 2.5% glutaraldehyde and fix overnight at 4℃; post-fixation: rinse 3 times with PBS for 15 min each time, and then fix with 1% osmium tetroxide solution at 4℃ for 2 h. The fixed samples were dehydrated using a gradient of ethanol (30%, 50%, 70%, 90%, and 100% ethanol, 15 min each), followed by resin infiltration: 2 h of infiltration was performed sequentially using resin-to-dehydrating agent mixtures at ratios of 1:2, 1:1, and 2:1, then overnight infiltration with pure resin. The fully infiltrated samples were transferred to embedding plates, and fresh resin was injected. The embedding plates were placed in a microwave tissue processor and polymerized for 48 h to form hardened resin blocks. The samples were then cut into 70–90 nm ultrathin sections using a cryo-microtome. The sections were observed under a transmission electron microscope, and the system acquired ultrastructural images of the bacteria in different treatment groups.
[0109] Transmission electron microscopy (TEM) images of Xanthomonas citrus as follows Figure 15 As shown, Figure 15 Image a in the diagram represents the negative control group, and image b represents the group treated with the antimicrobial peptide PJX13. Figure 15 It can be seen that the bacterial cells in the normal control group have intact structure, with the cell wall and cell membrane tightly attached, clear outline, and uniform and dense cytoplasm. Figure 15 (a) In this context, treatment with the antimicrobial peptide PJX13 resulted in significant morphological damage to the bacterial cells. Figure 15 (b) In this case, the cell wall is significantly thinner, rougher, and locally damaged; the cell membrane is severely ruptured and loses its integrity; the cytoplasm is unevenly distributed, condensing into electron-dense clumps of varying sizes, and a large number of cavities formed due to leakage of intracellular substances appear; the bacterial cells are severely shrunken and deformed, and most cells are so lysed that their original shape is difficult to identify, and the number of intact bacteria in the field of view is significantly reduced.
[0110] The above results indicate that the antimicrobial peptide PJX13 can effectively disrupt the integrity of the cell wall and cell membrane of Xanthomonas citrus, causing the internal structure of the cell to disintegrate, the contents to leak out, and ultimately leading to bacterial lysis and death, thus confirming its antimicrobial mechanism at the ultrastructural level.
[0111] The above embodiments are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the above embodiments. Any changes, modifications, substitutions, combinations, or simplifications made without departing from the spirit and principle of the present invention shall be considered equivalent substitutions and shall be included within the protection scope of the present invention.
Claims
1. An antimicrobial peptide PJX13, characterized in that, The antimicrobial peptide PJX13 was obtained by modifying the amino acid sequence shown in SEQ ID NO.1 with acetyl and amino capping.
2. The antimicrobial peptide PJX13 according to claim 1, characterized in that, The antimicrobial peptide PJX13 was acetylated at its N-terminus and amidated at its C-terminus.
3. An antibacterial composition, characterized in that, Contains the antimicrobial peptide PJX13 as described in claim 1 or 2.
4. The antibacterial composition according to claim 3, characterized in that, It also contains excipients.
5. The application of the antimicrobial peptide PJX13 according to claim 1 or 2, or the antimicrobial composition according to claim 3 or 4, in the fight against pathogenic bacteria, characterized in that, The pathogens are Escherichia coli, Staphylococcus aureus, Xanthomonas citrus, and / or rice blast fungus.
6. The use of the antimicrobial peptide PJX13 of claim 1 or 2 or the antimicrobial composition of claim 3 or 4 in the preparation of products for use against pathogenic bacteria, characterized in that, The pathogens are Escherichia coli, Staphylococcus aureus, Xanthomonas citrus, and / or rice blast fungus.
7. The use of the antimicrobial peptide PJX13 according to claim 1 or 2 in the preparation of products for the prevention and treatment of bacterial diseases, characterized in that, The bacterial disease is caused by infection with Escherichia coli and / or Staphylococcus aureus.
8. The use of the antibacterial composition according to claim 3 or 4 in the preparation of products for the prevention and treatment of bacterial diseases, characterized in that, The bacterial disease is caused by infection with Escherichia coli and / or Staphylococcus aureus.
9. The application of the antimicrobial peptide PJX13 according to claim 1 or 2 or the antimicrobial composition according to claim 3 or 4 in the prevention and control of plant diseases, characterized in that, The plant diseases mentioned are citrus canker and / or rice blast.
10. The use of the antimicrobial peptide PJX13 of claim 1 or 2 or the antimicrobial composition of claim 3 or 4 in the preparation of products for the prevention and control of plant diseases, characterized in that, The plant diseases mentioned are citrus canker and / or rice blast.
